Origen de la red de primer grado Lukas Jeker.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
Cimeio Therapeutics AG
 Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs.
4
| Holding Company | Packaged Software | 4 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Lukas Jeker a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Oxford | College/University | Doctorate Degree | |
Alentis Therapeutics AG
 Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chairman | |
| Versant Ventures (Switzerland) GmbH | Investment Managers | Private Equity Investor | |
Monte Rosa Therapeutics AG
 Monte Rosa Therapeutics AG Pharmaceuticals: MajorHealth Technology Monte Rosa Therapeutics AG develops, manufactures and distributes cancer drugs that modulate protein degradation pathways. The company was founded in 2018 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Enterprise Therapeutics Ltd.
 Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Biotechnology | Director/Board Member | |
| BLACK DIAMOND THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| Ridgeline Therapeutics | Chief Tech/Sci/R&D Officer | ||
| Imperial College London | College/University | Undergraduate Degree | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Director of Finance/CFO | |
| FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
T-Knife GmbH
 T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Biotechnology | Chairman | |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investment Managers | Corporate Officer/Principal | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Bright Peak Therapeutics, Inc.
 Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | Pharmaceuticals: Major | Director/Board Member | |
Launchpad Therapeutics, Inc.
 Launchpad Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Launchpad Therapeutics, Inc. develops novel therapeutics. | Miscellaneous Commercial Services | President | |
Vertical Bio AG
 Vertical Bio AG BiotechnologyHealth Technology Part of Pierre Fabre Participations SAS, Vertical Bio AG is a Swiss company that develops novel cancer therapies. The company is based in Basel, Switzerland. Vertical Bio was acquired by Pierre Fabre SA on September 12, 2023. | Biotechnology | Chairman | |
| MONTE ROSA THERAPEUTICS, INC. | Biotechnology | Chairman | |
| University of Wisconsin | College/University | Undergraduate Degree | |
| CRISPR THERAPEUTICS AG | Biotechnology | Director of Finance/CFO | |
Optimer Pharmaceuticals LLC
 Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Pharmaceuticals: Major | Director/Board Member | |
General Electric Healthcare Technologies, Inc.
 General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Medical/Nursing Services | Corporate Officer/Principal | |
| Motorola Automotive & Industrial Electronics Group | Corporate Officer/Principal | ||
| ABIOMED, INC. | Medical Specialties | Director of Finance/CFO | |
The Lexington
 The Lexington Medical/Nursing ServicesHealth Services Part of The Ensign Group, Inc., The Lexington operates a 125-bed assisted living facility. The company is based in Ventura, CA. | Medical/Nursing Services | Director of Finance/CFO | |
| MILESTONE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
| ACRIVON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Chief Executive Officer | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Founder | |
| University of Turin | College/University | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 18 |
| Suiza | 14 |
| Reino Unido | 4 |
| Alemania | 2 |
| Canadá | 2 |
Sectorial
| Health Technology | 26 |
| Consumer Services | 5 |
| Finance | 3 |
| Health Services | 3 |
| Commercial Services | 2 |
Operativa
| Director/Board Member | 18 |
| Corporate Officer/Principal | 7 |
| Chief Executive Officer | 6 |
| Director of Finance/CFO | 5 |
| Founder | 5 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Alexander Mayweg | 18 |
| Michael Tomsicek | 12 |
| Luca Santarelli | 12 |
| Thomas Fuchs | 1 |
- Bolsa de valores
- Insiders
- Lukas Jeker
- Conexiones Empresas
